PMGC Holdings Inc. (ELAB)Stock Price & Financial Statements
AboutPMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.Show more
- Revenue $2M +44.1%
- EBITDA -$2M +52.4%
- Net Income -$6M -45.2%
- EPS (Diluted) -274.68 +86.0%
- Gross Margin 72.84% +9.9%
- EBITDA Margin -72.28% +67.0%
- Operating Margin -75.65% +65.5%
- Net Margin -253.14% -0.8%
- ROE -119.12% +31.3%
- ROIC -82.69% +85.8%
- Debt/Equity -
- Interest Coverage -2.54 +98.7%
Key Insights
Based on financial data analysisStrengths
- ✓Share count reduced 96.7% through buybacks
- ✓Trading at only 0.0x book value
Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 4 (bottom 4%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y1339.59%
TTM-179.8%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-21.78%
EPS CAGR
10Y-
5Y-
3Y-
TTM89.91%
ROCE
10Y Avg-187.48%
5Y Avg-187.48%
3Y Avg-127.41%
Latest-33.67%
Peer Comparison
Microbiome and Phage Therapeutics| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
ELABPMGC Holdings Inc. | 23.88K | 1.05 | -0.00 | 44.07% | -253.14% | -78.44% | ||
 TOVXTheriva Biologics, Inc. | 252.1K | 0.19 | -0.01 | -388.69% | 0.08 | |||
 AZTRAzitra, Inc. | 2.03M | 0.19 | -0.08 | -100% | -0.29% | 0.11 | ||
 EVGNEvogene Ltd. | 7.31M | 0.84 | -0.29 | 50.9% | -52.33% | -15.93% | 0.87 | |
 SYBXSynlogic, Inc. | 7.02M | 0.60 | -0.31 | -99.76% | -2919.88% | -31.25% | ||
 MCRBSeres Therapeutics, Inc. | 80.02M | 9.13 | -0.48 | 15.37% | 12.34% | 6.65 | ||
 PHGEBiomX Inc. | 82.77B | 6.30 | -4.29 | -356.43% | 0.40 | |||
 ARMPArmata Pharmaceuticals, Inc. | 419.83M | 11.61 | -22.19 | 14.24% | -9.28% |
Compare ELAB vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 827 | 766.28K | 1.71M | 2.47M |
| Revenue Growth % | - | - | 92557.44% | 123.5% | 44.07% |
| Cost of Goods Sold | 0 | 2.85K | 318.97K | 578.01K | 670.2K |
| COGS % of Revenue | - | 344.01% | 41.63% | 33.75% | 27.16% |
| Gross Profit | 0 | -2.02K | 447.31K | 1.13M | 1.8M |
| Gross Margin % | - | -244.01% | 58.37% | 66.25% | 72.84% |
| Gross Profit Growth % | - | - | 22265.96% | 153.65% | 58.39% |
| Operating Expenses | 222.91K | 783.04K | 2.24M | 4.89M | 3.66M |
| OpEx % of Revenue | - | 94684.89% | 291.75% | 285.82% | 148.48% |
| Selling, General & Admin | 102.99K | 633.96K | 1.73M | 4.03M | 855.76K |
| SG&A % of Revenue | - | 76658.04% | 225.69% | 235.2% | 34.68% |
| Research & Development | 118.86K | 123.63K | 228.75K | 426.24K | 104.65K |
| R&D % of Revenue | - | 14949.46% | 29.85% | 24.89% | 4.24% |
| Other Operating Expenses | 0 | 25.45K | 277.48K | 440.45K | 2.7M |
| Operating Income | -221.84K | -785.06K | -1.79M | -3.76M | -1.87M |
| Operating Margin % | - | -94928.66% | -233.37% | -219.55% | -75.65% |
| Operating Income Growth % | - | -253.88% | -127.79% | -110.26% | 50.36% |
| EBITDA | 0 | -782.3K | -1.78M | -3.75M | -1.78M |
| EBITDA Margin % | - | -94595.28% | -232.52% | -218.87% | -72.28% |
| EBITDA Growth % | - | - | -127.76% | -110.38% | 52.42% |
| D&A (Non-Cash Add-back) | 221.84K | 2.76K | 6.51K | 11.65K | 83.1K |
| EBIT | -221.84K | -784.74K | -1.8M | -4.28M | -3.28M |
| Net Interest Income | 0 | 0 | 5.07K | -13.96K | -722.31K |
| Interest Income | 0 | 0 | 7.7K | 5.56K | 12.89K |
| Interest Expense | 0 | 0 | 2.63K | 19.52K | 735.2K |
| Other Income/Expense | -1.07K | 321 | -11.98K | -541.44K | -2.15M |
| Pretax Income | -222.91K | -784.74K | -1.8M | -4.3M | -4.02M |
| Pretax Margin % | - | -94889.84% | -234.94% | -251.17% | -162.8% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% | 100% | 155.49% |
| Net Income | -222.91K | -784.74K | -1.8M | -4.3M | -6.25M |
| Net Margin % | - | -94889.84% | -234.94% | -251.17% | -253.14% |
| Net Income Growth % | - | -252.04% | -129.41% | -138.94% | -45.2% |
| Net Income (Continuing) | -222.91K | -784.74K | -1.8M | -4.3M | -4.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | -2.23M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.08 | -0.29 | -0.67 | -1961.37 | -274.68 |
| EPS Growth % | - | -251.27% | -129.19% | -294842.11% | 86% |
| EPS (Basic) | -0.08 | -0.29 | -0.67 | -1961.37 | -274.68 |
| Diluted Shares Outstanding | 2.7M | 2.7M | 2.72M | 682.91K | 22.74K |
| Basic Shares Outstanding | 2.7M | 2.7M | 2.72M | 2.19K | 22.74K |
| Dividend Payout Ratio | - | - | - | - | - |
Balance Sheet
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 17.02K | 636.52K | 1.55M | 4.92M | 6.05M |
| Cash & Short-Term Investments | 13.35K | 411.86K | 1.15M | 3.33M | 3.98M |
| Cash Only | 13.35K | 411.86K | 1.15M | 3.33M | 3.98M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 1.71K | 12.85K | 36.16K | 5.28K |
| Days Sales Outstanding | - | 754.72 | 6.12 | 7.71 | 0.78 |
| Inventory | 0 | 160.82K | 230.15K | 495.67K | 1.04K |
| Days Inventory Outstanding | - | 20.63K | 263.36 | 313 | 0.57 |
| Other Current Assets | 3.67K | 0 | 0 | 0 | 1.19M |
| Total Non-Current Assets | 0 | 29.73K | 340.86K | 270.47K | 2.94M |
| Property, Plant & Equipment | 0 | 29.73K | 330.09K | 259.7K | 1.09K |
| Fixed Asset Turnover | - | 0.03x | 2.32x | 6.59x | 2269.82x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 2.8M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 139.08K |
| Other Non-Current Assets | 0 | 0 | 10.77K | 10.77K | 0 |
| Total Assets | 17.02K | 666.25K | 1.89M | 5.19M | 8.99M |
| Asset Turnover | - | 0.00x | 0.40x | 0.33x | 0.27x |
| Asset Growth % | - | 3814.05% | 184% | 174.28% | 73.28% |
| Total Current Liabilities | 40.61K | 215.62K | 588.27K | 1.3M | 1.8M |
| Accounts Payable | 154 | 98.17K | 210.84K | 596.15K | 481K |
| Days Payables Outstanding | - | 12.6K | 241.27 | 376.45 | 261.96 |
| Short-Term Debt | 24K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 10.17K | 36.69K | 0 |
| Other Current Liabilities | 16.46K | 0 | 68.45K | 369.16K | 548.92K |
| Current Ratio | 0.42x | 2.95x | 2.64x | 3.79x | 3.36x |
| Quick Ratio | 0.42x | 2.21x | 2.25x | 3.41x | 3.36x |
| Cash Conversion Cycle | - | 8.79K | 28.21 | -55.74 | -260.61 |
| Total Non-Current Liabilities | 0 | 0 | 172.6K | 65.49K | 534.47K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 172.6K | 65.49K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 534.47K |
| Total Liabilities | 40.61K | 215.62K | 760.87K | 1.36M | 2.33M |
| Total Debt | 24K | 0 | 283.22K | 210.49K | 0 |
| Net Debt | 10.65K | -411.86K | -871.68K | -3.12M | -3.98M |
| Debt / Equity | - | - | 0.25x | 0.06x | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | -680.22x | -192.58x | -2.54x |
| Total Equity | -23.59K | 450.63K | 1.13M | 3.83M | 6.66M |
| Equity Growth % | - | 2010.33% | 151.05% | 238.29% | 74.01% |
| Book Value per Share | -0.01 | 0.17 | 0.42 | 5.60 | 292.88 |
| Total Shareholders' Equity | -23.59K | 450.63K | 1.13M | 3.83M | 6.66M |
| Common Stock | 848 | 952 | 957 | 1.73K | 44 |
| Retained Earnings | -137.37K | -922.11K | -2.72M | -7.02M | -13.27M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.22K | 202 | 111 | 202 | -337 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | -217.16K | -660.93K | -1.59M | -4.56M | -5.49M |
| Operating CF Margin % | - | -79919.47% | -206.96% | -266.08% | -222.39% |
| Operating CF Growth % | - | -204.35% | -139.94% | -187.34% | -20.41% |
| Net Income | -222.91K | -784.74K | -1.8M | -4.3M | -6.25M |
| Depreciation & Amortization | 0 | 2.76K | 6.51K | 11.65K | 12.95K |
| Stock-Based Compensation | 0 | 142.35K | 171.87K | 487.74K | 97.17K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.04K | 600 | 23.58K | 68.51K | 396.97K |
| Working Capital Changes | 6.79K | -21.91K | 12.43K | -823.19K | 251.67K |
| Change in Receivables | -605 | -1.35K | -11.55K | -23.22K | -12.97K |
| Change in Inventory | 0 | -160.82K | -69.33K | -265.52K | -403.3K |
| Change in Payables | 0 | 192.09K | 65.19K | 466.89K | 207.5K |
| Cash from Investing | 0 | -32.48K | -32.03K | -11.19K | -610.56K |
| Capital Expenditures | 0 | -32.48K | -35.53K | -11.19K | -9.16K |
| CapEx % of Revenue | - | 3927.69% | 4.64% | 0.65% | 0.37% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | 3.5K | 0 | -462.32K |
| Cash from Financing | 238.28K | 1.09M | 2.36M | 6.74M | 6.76M |
| Debt Issued (Net) | 0 | 0 | 183.97K | 0 | -235.56K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 238.28K | 0 | 25K | -724.7K | 0 |
| Net Change in Cash | 19.61K | 398.51K | 743.04K | 2.17M | 657.6K |
| Free Cash Flow | -217.16K | -693.42K | -1.62M | -4.57M | -5.49M |
| FCF Margin % | - | -83847.16% | -211.59% | -266.73% | -222.39% |
| FCF Growth % | - | -219.31% | -133.83% | -181.73% | -20.12% |
| FCF per Share | -0.08 | -0.26 | -0.60 | -6.69 | -241.31 |
| FCF Conversion (FCF/Net Income) | 0.97x | 0.84x | 0.88x | 1.06x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -367.53% | -227.6% | -173.5% | -119.12% |
| Return on Invested Capital (ROIC) | - | -4559% | -898.95% | -581.25% | -82.69% |
| Gross Margin | - | -244.01% | 58.37% | 66.25% | 72.84% |
| Net Margin | - | -94889.84% | -234.94% | -251.17% | -253.14% |
| Debt / Equity | - | - | 0.25x | 0.06x | - |
| Interest Coverage | - | - | -680.22x | -192.58x | -2.54x |
| FCF Conversion | 0.97x | 0.84x | 0.88x | 1.06x | 0.88x |
| Revenue Growth | - | - | 92557.44% | 123.5% | 44.07% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics